{"entity":{"id":"nct02944357","kind":"trial","name":"Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery","aka":[],"tldr":"An trial of Rocapuldencel-T run by Mayo Clinic, withdrawn before enrolling.","summary":"Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery is an interventional study registered as NCT02944357 by Mayo Clinic, started 2016-11. Conditions recorded: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma and Stage IV Bladder Urothelial Carcinoma. Interventions recorded: Cisplatin, Gemcitabine Hydrochloride, Radical Cystectomy and Tumor Cell-Derived Vaccine Therapy.","status":"withdrawn","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02944357","url":"https://clinicaltrials.gov/study/NCT02944357"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["rocapuldencel-t"],"companies":["argos-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02944357","phase":"not-applicable","setting":"Pilot Study of Gemcitabine and Cisplatin Plus AGS-003-BLD in Patients With Muscle-Invasive Bladder Cancer Undergoing Neoadjuvant Cisplatin-Based Chemotherapy","sponsor":"Mayo Clinic","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02944357/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"rocapuldencel-t","kind":"drug","name":"Rocapuldencel-T","route":"/drugs/rocapuldencel-t/"}],"company":[{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","route":"/companies/argos-therapeutics/"}]}}